AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02630706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg oral tablet taken once daily
Study NCT02630706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily
Study NCT02630706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching ertugliflozin
Description: Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
Study NCT02630706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ertugliflozin
Description: Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
Study NCT02630706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to >= 1500 daily.
Study NCT02630706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to >= 1500 daily.
Study NCT02630706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
Study NCT02630706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
Study NCT04054414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline along with standard treatment
Description: The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
Study NCT04054414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-1620 along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Study NCT02626442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 month group exercise class
Study NCT03045913 — intervention group
Intervention type: DEVICE
Intervention: Genoss DES
Description: The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Study NCT05980962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior oblique anteriorization
Description: symmterical anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion
Study NCT01368887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Monotherapy
Description: The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
Study NCT00430456 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise
Description: Treadmill Training
Study NCT00430456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Treadmill Training
Study NCT03682029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid)
Description: Monotherapy with oral vitamin C supplementation to elevate plasma vitamin C level to the upper end of the physiological range.
Study NCT03682029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00284154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: 320mg/m2 every 21 days as a 15-20 minute infusion
Study NCT04624542 — intervention group
Intervention type: DEVICE
Intervention: Electromyographic device
Description: the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS
Study NCT04516863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: German Autobiographical Memory Interview short-form
Description: Diagnostic Test
Study NCT00591019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg/day, morning dose
Study NCT00591019 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill once per day in the morning.
Study NCT00657995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas (STG-22)
Description: safe tool
Study NCT05980962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior oblique anteriorization together with unliateral resction
Description: asymmterical surgery, anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion in one eye, and an additional 3-5 mm resction of the inferior oblique in the eye with the larger devation
Study NCT00845676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a + Ribavirin
Description: Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
Study NCT02535377 — intervention group
Intervention type: OTHER
Intervention: Sperm cryopreservation
Description: Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
Study NCT01033708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: narrative exposure therapy
Description: Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
Study NCT01033708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: narrative exposure therapy
Description: Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
Study NCT01904747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib administered Fasted
Description: palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
Study NCT01904747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib administered Fed high calorie
Description: palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
Study NCT02050698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protected weightbearing in a hard-soled shoe
Description: Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
Study NCT01904747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib administered Fed low calorie
Description: palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
Study NCT01904747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib administered Fed moderate calorie
Description: palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
Study NCT03996564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Battlefield Acupuncture
Description: 1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.
Study NCT03996564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 500mg-1000mg,
Study NCT03996564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Diclofenac 50mg-75 mg orally
Study NCT03996564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Diazepam 5mg-10 mg intravenous or oral
Study NCT03996564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone
Description: Hydrocodone 5mg/325mg-10mg/650mg mg
Study NCT03996564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: oral, or intramuscular Ketorolac 30mg-60 mg
Study NCT02830932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-RSV-f Tablets (high dose)
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.
Study NCT02830932 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VXA Placebo Tablets
Description: The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
Study NCT02830932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-RSV-f Tablets (low dose)
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose
Study NCT04456166 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: noNPO
Description: Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting will be asked to be enrolled into the study.~Before induction of general anesthesia, all patients were evaluated the gastric volume under ultrasonography.
Study NCT04374292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family intervention
Description: Topics covered in each session with intervention group mothers.~1. Dietary and physical activity habits and their link to obesity and cardio-metabolic diseases. Children learn about healthy eating habits and health risks at home.~2. Food-preparation processes. Selecting and purchasing food and beverages; importance of food groups and their impact on health; importance of fruit and vegetables. Balance between food groups, source of foods, organic or industrialized. Family menu preparation.~3. Habits and behaviors surrounding eating processes identified as health or risk factors, such as energy density, portion-size control, controlling emotional eating.~4. Beverages. Water versus sugar-sweetened drinks prepared at home or purchased at the store.~5. Preventing the risk of cardiovascular diseases by learning healthy eating habits and practicing these habits at home.~6. Integration. Practicing the skills learned during the intervention in each stage of preparing food and eating
Study NCT04374292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual nutritional consultation
Description: Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
Study NCT02050698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protected weightbearing in a short leg walking cast
Description: Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
Study NCT04482036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Phone Application Assessments
Description: The BrainCare Notes app was designed to be installed on the caregiver's phone. It has the capacity to send Neuropsychiatric Inventory Questionnaire (NPI-Q) assessments to the caregiver. If the answers to the behavioral and psychological symptoms rise above the threshold, the clinicians will be notified, and a care plan will be enacted, in order to keep the patient and caregiver safe.~The application also has the ability to send and receive private messages between caregiver and the patient's clinical care team.
Study NCT04482036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Assessments
Description: The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.
Study NCT04482036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Assessments
Description: The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.
Study NCT02578940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine PET CT
Description: Radioligand for PET CT scanning
Study NCT01309451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: intravitreal, 1.25mg., monthly
Study NCT01309451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone intravitreal implant
Description: 0.7mg, intravitreal every 4 months
Study NCT00482599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: 2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
Study NCT00482599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: 2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
Study NCT02295787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal ketamine for late-life depression and suicidal ideation.
Study NCT02295787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00614757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 20% 4ml
Description: N-acetylcysteine 20% 4ml
Study NCT00614757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 20% in 4 ml
Description: N-acetylcysteine 20% in 4 ml
Study NCT02795468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial arterial cannulation
Description: Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
Study NCT02795468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial arterial cannulation
Description: Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
Study NCT03693001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Exposure to Oxygen via Oro-Nasal Mask
Description: Patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ATA) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask for 40 treatments over a 2 month period.
Study NCT04501016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored behavioral counseling
Description: Participants will initially receive a six-session telephone intervention. Standard cognitive behavioral treatment strategies will be included. Participants will be screened for elevated depressive symptoms, risky alcohol use, and concerns about weight and and offered supplemental behavioral counseling related to these issues as appropriate. Those that are unable to quit tobacco initially will receive an enhanced, four-session counseling module focused on reduced scheduled smoking. Those who do quit tobacco use initially will receive four sessions of extended counseling based on positive psychology intervention strategies.
Study NCT04501016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobacco cessation pharmacotherapy
Description: Pharmacotherapy will be selected based on medical and psychiatric history and potential interactions with other current medications combined with shared decision making. Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily). Monotherapy and combination therapy options will be provided.
Study NCT01922154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab
Description: The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
Study NCT01922154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with mitomycinC
Description: All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
Study NCT02820181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel tracheostomy bi-ties
Description: The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
Study NCT02820181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional Tracheostomy ties
Description: Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
Study NCT00524680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally
Study NCT01603394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
Study NCT02617134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MUC1 CAR-T cells
Study NCT04148235 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT00384371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Botulinum Toxin A
Study NCT00384371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04432454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene and abemaciclib (VERZENIO (R)).
Description: Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
Study NCT00371995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B and Miltefosine
Description: Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)
Study NCT04422977 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sars-Cov-2 serology
Description: Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
Study NCT03831269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
Study NCT03831269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nbUVB
Description: The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
Study NCT01065363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standardized exercise program and dietary counseling
Description: Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
Study NCT03519113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102 80,000 IU
Description: recombinant human hepatitis B immunoglobulin
Study NCT03519113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102 100,000 IU
Description: recombinant human hepatitis B immunoglobulin
Study NCT03519113 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: I.V HBIG
Description: human anti-hepatitis B Immunoglobulin
Study NCT02343380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calorimetric exam after a standard meal
Description: The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
Study NCT01259674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AboMeg-B-09
Description: Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
Study NCT01259674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup: 5ml to be taken 4 times a day during the entire study period
Study NCT01733823 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole